5-MeO-DMT, a naturally occurring psychoactive drug, is metabolized by the enzyme CYP2D6 into the active metabolite bufotenine and is mainly inactivated by MAO-A. When taken with MAO-A inhibitors like harmaline, deamination is reduced, leading to prolonged exposure to both 5-MeO-DMT and bufotenine. These compounds act together on serotonin systems, potentially causing serotonin toxicity. CYP2D6 also metabolizes harmaline, and genetic variations in this enzyme may alter drug interactions and risks. This review covers the metabolism, pharmacokinetics, and drug-drug interactions of 5-MeO-DMT with harmaline, along with risks of intoxication.
The hallucinogen 2C-T-7 produces head twitch responses in mice and serves as a discriminative stimulus in rats, effects that are blocked by a selective 5-HT2A antagonist. In drug discrimination tests, 2C-T-7 partially generalized (75%) to the LSD cue in rats and acted as a discriminative stimulus itself, with those interoceptive effects also attenuated by the 5-HT2A antagonist. Binding studies show 2C-T-7 has nanomolar affinity for 5-HT2A and 5-HT2C receptors and lower affinity for 5-HT1A receptors. The antagonism of its behavioral effects strongly suggests the 5-HT2A receptor is an important site of action for this compound.